Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Islam M, Ghazi"'
Autor:
Wasim S. El Nekidy, Mooza Al Ali, Emna Abidi, Rania El Lababidi, Diaa Alrahmany, Islam M. Ghazi, Mohamad Mooty, Fadi Hijazi, Muriel Ghosn, Jihad Mallat
Publikováno v:
Antibiotics, Vol 13, Iss 8, p 699 (2024)
The optimal doses of ceftazidime–avibactam (CZA) and ceftolozane–tazobactam (C/T) for treating multidrug-resistant (MDR) Pseudomonas aeruginosa (PSA) in patients utilizing renal replacement therapy (RRT) are not well established. Hence, the objec
Externí odkaz:
https://doaj.org/article/80d5d2a1c0414dcb8eb4d9060cb58a55
Autor:
Islam M. Ghazi, Wasim S. El Nekidy
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/ab9d3973279b4065b6ac8f7265f69cf4
Autor:
Diaa Alrahmany, Benjamin J. Ereshefsky, Wasim S. El Nekidy, Gehan Harb, Laura Pontiggia, Islam M. Ghazi
Publikováno v:
Journal of Infection and Public Health, Vol 14, Iss 11, Pp 1642-1649 (2021)
Background: Diarrhea and pseudomembranous colitis associated with Clostridioides difficile – a spore-forming anaerobic Gram-positive bacillus – is a major infection in hospitalized patients with a profound impact on clinical and economic outcomes
Externí odkaz:
https://doaj.org/article/3be2a8d186ef478487f6bbf98e1605aa
Publikováno v:
Antibiotics, Vol 12, Iss 3, p 494 (2023)
Disturbances in the count or maturity of blood cells weaken their microbial defensive capacity and render them more susceptible to infections. Glucose-6-phosphate deficient patients are affected by a genetic disease that affects cell integrity with i
Externí odkaz:
https://doaj.org/article/c6cd418bdcfd467eb941eb5e7d4624db
Autor:
Diaa Al Rahmany, Adel Albeloushi, Iman Alreesi, Ahmed Alzaabi, Mohammed Alreesi, Laura Pontiggia, Islam M. Ghazi
Publikováno v:
International Journal of Infectious Diseases, Vol 83, Iss , Pp 77-82 (2019)
Background: Increasing rate of resistant infections is a challenge to healthcare negatively impacting therapeutic and financial outcomes. Targeted antimicrobial stewardship interventions are needed to counteract this global crisis. On large scale, we
Externí odkaz:
https://doaj.org/article/533df78255994d20a7f22ddf99e04d8c
Publikováno v:
Antibiotics, Vol 11, Iss 8, p 1086 (2022)
Due to resistance and scarcity of treatment options, nosocomial Acinetobacter baumannii infections are associated with significant fatality rates. We investigated the factors contributing to infection-related deaths to develop tailored stewardship in
Externí odkaz:
https://doaj.org/article/d78352493d804d7f8a1ee4b214f54a56
Publikováno v:
Antibiotics, Vol 11, Iss 7, p 934 (2022)
G6PD deficiency is a genetic disease that weakens the immune system and renders affected individuals susceptible to infections. In the Sultanate of Oman resides a high number of recorded G6PD cases due to widespread consanguineous marriage, which may
Externí odkaz:
https://doaj.org/article/728db6c216c84dd6b8ae50445e921a70
Publikováno v:
IDCases, Vol 20, Iss , Pp e00748- (2020)
Providing care for patients with chronic kidney disease requires considerations that are unique to this population. Several references recommend the treating urinary tract infections with antibiotics that achieve considerable concentrations in urine
Externí odkaz:
https://doaj.org/article/4404fd88ba184bb5b9a1e2b676f4c136
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0235405 (2020)
[This corrects the article DOI: 10.1371/journal.pone.0233335.].
Externí odkaz:
https://doaj.org/article/937ada9c97c5474c9847c3f48cc6d634
Publikováno v:
PLoS ONE, Vol 15, Iss 5, p e0233335 (2020)
Imipenem/cilastatin/relebactam is a β-lactam/β-lactamase inhibitor that has been recently FDA approved for complicated intra-abdominal and urinary tract infections under the brand name Recarbrio®. It has activity against imipenem non-susceptible P
Externí odkaz:
https://doaj.org/article/827d302122f740b6930e84d99ad435a7